Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, September 20, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Agilent Solutions for SFC with Mass Spectrometric Detection
Tuesday, June 17, 2014
Company’s solutions for supercritical fluid chromatography streamline high-volume analysis of complex compounds.

Protea Announces HRAM Analytical Services
Tuesday, June 17, 2014
Adds HRAM to its mass spectrometry based molecular imaging and LC-MS bioanalytical services portfolio.

AB SCIEX StatusScope™ Remote Monitoring Service Enables Trouble-Shooting and Control via Smartphone
Tuesday, June 17, 2014
Sophisticated, User-Configurable Service Minimizes Downtime.

Owlstone Introduces UltraFAIMS for Improved Mass Spectrometry
Monday, June 16, 2014
A low-cost accessory for mass spectrometers that provides an additional dimension of high-speed separation by ion mobility.

Software Automates Deep Characterization of Biotherapeutic Proteins
Monday, June 16, 2014
A new software tool, Thermo Scientific PepFinder, is designed to increase the speed, quality and accuracy in comprehensive biotherapeutic protein characterization during drug development and production quality control.

New High Resolution Accurate Mass LC-MS System Scans 50 Percent Faster than Predecessor
Monday, June 16, 2014
When it comes to pursuing breakthroughs in proteomics research, there’s no such thing as too much scanning speed, as long as data quality remains high. The latest addition to the industry-leading Q Exactive family of Thermo Scientific liquid chromatography-mass spectrometry (LC-MS) systems addresses this demand.

Next Generation Triple Quadrupole GC-MS Designed to be More Sensitive and Three Times Faster than Predecessor
Monday, June 16, 2014
Laboratories analyzing food, the environment, and biological samples for compounds like dioxins, PCBs, pesticides, steroids and other challenging analytes now have access to a new generation of GC-MS/MS from Thermo Fisher Scientific, designed to deliver more sensitivity at faster speeds than its predecessor.

New Mass Spectrometric Immunoassay Consumables Enable Large Biomolecule Analysis
Monday, June 16, 2014
The new functionalized pipette tips feature proprietary microcolumn technology designed to enable enhanced, reproducible target purification and reduce complexity in biological samples prior to liquid chromatography-mass spectrometry (LC-MS) protocols.

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions
Monday, June 16, 2014
The products for life-science research, clinical research, biopharma and applied markets were announced at the 62nd ASMS Conference on MS.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 772
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv